title: Medical treatment of primary sclerosing cholangitis.
abstract: Until 1970, primary sclerosing cholangitis (PSC) was considered to be a medical curiosity. With the development of endoscopic cholangiography, PSC is now recognized more frequently and is a common indication for liver transplantation. PSC is usually progressive, leading to cirrhosis, portal hypertension, and liver failure. The manifestations of disease may be clinically similar to those of other causes of bile duct obstruction and must be distinguished from gallstone disease, bile duct carcinoma, primary biliary cirrhosis, and secondary biliary cirrhosis due to bile duct stricture. Medical management of PSC must take into account the likelihood that destroyed bile ducts do not regenerate as hepatocytes do. Hence, PSC should be treated early in its course. The goal of therapy is to prevent further damage and destruction of bile ducts. In this article, we will present relevant data concerning the medical management of primary sclerosing cholangitis.
authors.affiliation: Division of Gastroenterology, New England Medical Center, Tufts School of Medicine, 750 Washington Street, Box 002, Boston, MA 02111, USA.
authors.forename: Y M
authors.initials: YM
authors.lastname: Lee
authors.forename: M M
authors.initials: MM
authors.lastname: Kaplan
mesh_terms: D015209:Cholangitis, Sclerosing / Q000150:complications / Q000188:drug therapy*; D002779:Cholestasis / Q000150:complications / Q000188:drug therapy; D006801:Humans; D013997:Time Factors